



ORION PHARMA LIMITED

Registered Office: Orion House, 153-154 Tejgaon I/ A, Dhaka

UN-AUDITED HALF YEARLY (Q2) FINANCIAL STATEMENTS

This is to inform you all concerned that the un-audited condensed consolidated financial statements of Orion Pharma Limited as on and for the Half Yearly (Q2) period ended on December 31, 2025 has been adopted by the Board of Directors in its meeting held on January 29, 2026 at 4:00 pm in the registered office at Orion House, 153-154 Tejgaon I/ A, Dhaka-1208. The excerpts of the Financial Statements are as follows:

Particulars		July-Dec	July-Dec	Oct-Dec	Oct-Dec
		2025	2024	2025	2024
Consolidated Earnings Per Share (EPS) - Q2	:	BDT (0.86)	BDT (0.20)	BDT (0.56)	BDT (0.44)
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q2	:	BDT 2.61	BDT 4.26	--	--
		December 31, 2025		June 30, 2025	
Consolidated Net Asset Value (NAV) per Share - Q2 (Including Revaluation Surplus)	:	BDT 85.74		BDT 86.09	
Consolidated Net Asset Value (NAV) per Share - Q2 (Excluding Revaluation Surplus)	:	BDT 78.00		BDT 78.34	

The detailed Financial Statements are also available in the Company's website: www.orionpharma.com

Sd/-

Md. Ferdous Jaman

Company Secretary

Date: January 29, 2026